Head-to-head evidence
ecnoglutide vs liraglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ecnoglutide
Marketed by Sciwind Biosciences
NCT05813795 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled Phase 3 trial in 664 adults with overweight or obesity. Ecnoglutide 2.4 mg produced a significantly greater reduction in body weight than placebo at week 40, -13.2% vs +0.1%, p<0.0001, meeting the trial primary comparison.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT07553299 (registry estimate)
liraglutide · Saxenda / Victoza
Marketed by Novo Nordisk
NCT00781937 · Phase 3 · completed
The trial randomly assigned 212 participants to liraglutide and 210 to placebo in a double-blind, placebo-controlled design, with objective body-weight outcomes assessed at week 56. All three prespecified primary comparisons favored liraglutide and were statistically significant (each p<0.0001), supporting a strong evidence grade.
Next expected readout: December 2026 · NCT07225816 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ecnoglutide's landscape · liraglutide's landscape